A new study published in the scientific journal Circulation has found that the prolonged use of aspirin in high-risk cardiovascular patients with stents may be ineffective or even harmful. The study focused on over 7,500 patients with acute coronary syndrome, which includes heart conditions caused by a sudden decrease in blood flow to the heart, such as heart attacks. These patients underwent percutaneous coronary intervention, a common procedure where a stent is inserted to keep the blocked artery open. Typically, doctors recommend a combination of an antiplatelet medication and aspirin for about a year to prevent blood clots after stent placement.
However, the study revealed that removing aspirin from the treatment regimen after three months was equally effective in preventing clotting complications, but significantly reduced the risk of severe bleeding that aspirin can cause. Dr. Roxana Mehran, the study's principal investigator, questioned the necessity of using aspirin alongside potent anti-clotting agents. She highlighted the potential of aspirin to significantly increase the risk of bleeding without offering significant benefits.
Cardiovascular diseases are the leading cause of death globally, responsible for nearly 18 million deaths each year. Over the years, medical professionals have often recommended regular aspirin as a preventive measure against heart problems, as it can reduce blood clotting and lower the risk of heart attacks and strokes. However, aspirin can also increase the risk of severe bleeding, particularly in older individuals.
As a result, in 2019, leading medical associations shifted their stance on daily aspirin use, no longer recommending it as a preventive measure for older adults without a high risk or existing heart disease. The United States Preventive Services Task Force also recommended against daily aspirin for individuals over 60 in 2022. Nonetheless, many healthcare professionals still consider aspirin beneficial for patients with heart problems or stents. The recent study's findings challenge this assumption.
Researchers analyzed patient data from two large clinical trials and found that patients who discontinued aspirin after three months had outcomes similar to those who continued the aspirin-ticagrelor combination therapy. Both groups had comparable rates of death, heart attacks, and strokes. Moreover, discontinuing aspirin reduced the risk of severe bleeding by nearly 50% without increasing the risk of cardiac complications. This observation suggests that aspirin might not be necessary in long-term treatment for acute coronary syndrome patients with stents.
Experts believe that these findings could lead to a new standard of care for high-risk cardiac patients. Dr. Mehran, influenced by the study's results and existing evidence, now prescribes a treatment plan without long-term aspirin for her patients. She even suggests removing aspirin earlier, potentially after just one month, which is currently being investigated in ongoing studies.
It's important to note that aspirin remains a beneficial medication for heart conditions. The study's results don't apply to patients with other heart problems requiring blood thinners. The focus was specifically on high-risk patients recovering from acute coronary syndrome and stent placement, where discontinuing aspirin relied on the patients taking ticagrelor for at least a year. Additionally, patients needed to complete three months of combination therapy without complications before aspirin was removed from their treatment plan.
Dr. Harlan Krumholz, a cardiologist and professor at the Yale School of Medicine, emphasizes the essential role of aspirin in the first three months after receiving a stent for a heart attack, stating that it remains an important treatment. He believes that further research into simplifying medication plans could improve patient outcomes, suggesting that withdrawing unnecessary medications may actually benefit patients. This study sheds light on how we can safely simplify drug regimens and improve patient outcomes by subtracting drugs.